New Delhi, India – 110 016

South Delhi Pharma, New Delhi, India

Anktiva (nogapendekin alfa inbakicept-pmln)

This specialty medication is authorized and manufactured internationally and is not registered or commercially distributed for retail sale in India. To verify patient eligibility, check international supply availability, or understand the regulatory logistics and documentation process: Call our Compliance Desk at 9891296838 or Email your Inquiry query@southdelhipharma.com.

ANKTIVA is a drug to activate the immune system (the body system that helps fight disease) used together with another drug called Bacillus Calmette-Guerin (BCG) to treat a subtype of non-muscle invasive bladder cancer (NMIBC), called carcinoma in situ (CIS). It is used in patients for whom BCG treatment was not effective in treating their bladder cancer. This means that the disease either did not improve on treatment or recurred following treatment with BCG.

Brand Name: Anktiva
Active Ingredient: nogapendekin alfa inbakicept-pmln
Dosage Forms And Strengths: • 400 mcg/0.4 mL, clear to slightly opalescent and colorless to slightly yellow solution in single-dose vials for intravesical instillation after dilution
Manufacturer: Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc.
FDA-approved use on approval date: Treatment of bladder cancer
Price: On Request

Do you need this medicine in India?

To help you get this medicine – Anktiva (nogapendekin alfa inbakicept-pmln), a prescription from the Registered Medical Practitioner (RMP) is required. Contact Mr. Tarun at 9891296838 via Call or WhatsApp for availability in India.

Category
Category

Disclaimer: Trademark shown are property of their respective owners and South Delhi Pharma (SDP) India does not lay any claim on them.

Get In Touch

South Delhi Pharma is dedicated to facilitating access to critical, globally approved pharmaceutical therapies tailored to individual patient needs. Established in 1996, It has built a trusted reputation for assisting patients and healthcare institutions in navigating the regulatory frameworks required to securely source high-quality, international life-saving medications.

The SDP is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

Query Form

This is an inquiry and facilitation request form. Submission does not constitute a sale, purchase order, or guarantee of medicine availability.

Description

Nogapendekin alfa inbakicept is indicated with Bacillus Calmette-Guérin for adults with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors.

Nogapendekin alfa inbakicept was approved for medical use in the United States in April 2024. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

ANKTIVA (nogapendekin alfa inbakicept-pmln) solution, for intravesical use Initial U.S. Approval: 2024

See full prescribing information: Click Here

Get Access To Anktiva (nogapendekin alfa inbakicept-pmln) In India on request

Brand Name “Anktiva” or Generic Name “nogapendekin alfa inbakicept-pmln” can be imported for personal use under “Named Patient Program” treatment in Delhi, Kolkata, Surat, Jaipur, Noida, Gurgaon (Gurugram), Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura and Sikkim, Noida, Kanpur, Lucknow, Dehradun, Shimla, Ahmedabad, Jodhpur, Mumbai, Jaipur, Aurangabad, Pune, Bangalore, Hyderabad, Chennai, Visakhapatnam, Coimbatore, Andhra Pradesh, Karnataka, Kerala, Lakshadweep, Puducherry, Tamil Nadu, Telangana, India. Contact us at support@southdelhipharma.net, southdelhipharma@gmail.com or  you can call at 9891296838 or WhatsApp at 9891296838

Related Products